Growth HormoneWell StudiedPrescription

Tesamorelin

Also known as: Egrifta, Egrifta SV, TH9507, Tesamorelin Acetate

Tesamorelin is a synthetic 44-amino-acid GHRH analog that was FDA-approved in 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It is the only GHRH analog with full FDA approval for a specific clinical indication. Tesamorelin stimulates the pituitary gland to produce and release growth hormone in a physiological, pulsatile manner, preserving the hypothalamic-pituitary feedback loop. Clinical trials demonstrated significant reductions in visceral adipose tissue (VAT) — averaging 15-18% reduction — along with improvements in trunk fat, lipid profiles, and IGF-1 levels. It is increasingly used off-label in anti-aging and body composition protocols due to its favorable safety profile and strong evidence base.

Research Score9/10

Extensive clinical evidence

Safety Score9/10

Well-tolerated with minimal side effects

How It Works

Tesamorelin is a synthetic GHRH analog that binds to GHRH receptors on anterior pituitary somatotroph cells, stimulating synthesis and pulsatile release of endogenous growth hormone. This increases IGF-1 production, which promotes lipolysis in visceral adipose tissue.

Key Benefits

FDA-approved for visceral fat reduction
Stimulates natural pulsatile growth hormone release
Significant reduction in trunk and abdominal fat
Increases IGF-1 levels within physiological range
Improves lipid profiles (triglycerides, cholesterol ratios)
Preserves hypothalamic-pituitary feedback mechanisms
May improve cognitive function in older adults

Who May Benefit

Adults with excess visceral abdominal fat resistant to lifestyle changes
Individuals over 40 with age-related growth hormone decline
Patients seeking the most evidence-backed GH secretagogue
Those wanting FDA-approved peptide therapy for body composition

Dosage & Administration

Typical Dosage

Once daily, typically administered in the morning

Cycle Length

6-12 months; ongoing use under medical supervision

Administration Routes

subcutaneous

Expected Timeline

IGF-1 levels increase within 2-4 weeks. Measurable visceral fat reduction at 8-12 weeks. Optimal body composition changes at 6-12 months.

Safety Information

Possible Side Effects

Injection site reactions (erythema, pruritus, pain)Joint pain (arthralgia)Peripheral edemaMyalgiaParesthesia (tingling in extremities)Elevated blood glucose (transient)

Contraindications

Active malignancy or history of cancerDisruption of the hypothalamic-pituitary axis (surgery, radiation, trauma)Pregnancy or breastfeedingKnown hypersensitivity to tesamorelin or mannitolPituitary gland surgery or disease

Dr. Taylor's 2 Cents

“Tesamorelin is unique among GH secretagogues because it's the only one with full FDA approval — that tells you a lot about the quality of evidence behind it. I use it primarily for patients struggling with visceral abdominal fat that doesn't respond to diet and exercise alone. The visceral fat reduction data is impressive and consistent across multiple trials. Compared to sermorelin or CJC-1295, tesamorelin has the strongest evidence base for body composition changes. The trade-off is cost — it's significantly more expensive than other GHRH analogs.”

Discuss with Dr. Taylor →

Frequently Asked Questions

What is Tesamorelin?

Tesamorelin is an FDA-approved synthetic GHRH analog that stimulates your pituitary gland to produce growth hormone naturally, primarily used to reduce visceral abdominal fat.

Is Tesamorelin FDA approved?

Yes — it was FDA-approved in 2010 (brand name Egrifta) for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. It is also used off-label for growth hormone optimization.

How does Tesamorelin differ from Sermorelin?

Both are GHRH analogs, but tesamorelin is a longer 44-amino-acid peptide with FDA approval and stronger clinical evidence for visceral fat reduction. Sermorelin (29 amino acids) has a longer general track record but less fat-reduction data.

What are the main side effects?

Most common are injection site reactions, joint pain, and mild swelling. Blood glucose may increase slightly and should be monitored.

How long does it take to see results?

IGF-1 increases within weeks. Visible fat reduction typically appears at 2-3 months, with optimal results at 6-12 months of consistent use.

Who should not use Tesamorelin?

People with active cancer, pituitary disorders, or disruption of the hypothalamic-pituitary axis. Pregnancy is a contraindication.

Published Research

Effects of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation

Falutz J, Allas S, Blot K, et al. · Journal of Acquired Immune Deficiency Syndromes (2010)

Key Finding: Tesamorelin significantly reduced visceral adipose tissue by 15.2% versus a 5% increase with placebo over 26 weeks, with concurrent improvements in triglycerides and cholesterol ratios.

PubMed →DOI →

Tesamorelin, a Growth Hormone-Releasing Factor Analogue, Improves Visceral Adiposity and Metabolic Parameters in HIV-Infected Patients

Falutz J, Potvin D, Mamputu JC, et al. · The Lancet (2007)

Key Finding: Phase 3 trial showed tesamorelin reduced trunk fat by 15.4% and visceral fat by 27.8% at 26 weeks, with significant increases in IGF-1 and improvements in patient-reported body image.

PubMed →DOI →

Growth Hormone-Releasing Hormone in HIV-Infected Men With Lipodystrophy: A Randomized Controlled Trial

Lo J, You SM, Canavan B, et al. · JAMA (2008)

Key Finding: GHRH analog treatment reduced visceral fat by 20%, improved triglyceride-to-HDL ratio, and increased growth hormone and IGF-1 levels without worsening glucose tolerance.

PubMed →DOI →

Protocols Featuring Tesamorelin

Body Recomposition Protocol

Metabolic optimization for weight loss

Men's Longevity & Vitality Protocol

Anti-aging and cellular optimization

Related Peptides

Want personalized guidance?

Consult with Dr. Patrick Taylor for a comprehensive evaluation and personalized protocol.

Book a Consultation

Medical Disclaimer: This information is for educational purposes only and is not medical advice. Consult a healthcare provider before starting any peptide protocol.